Thursday, 14 December 2023 | PNS | DEHRADUN
‘Himalayan School of Biosciences under the Swami Rama Himalayan University (SRHU) Jollygrant has claimed that a new stent invented by its assistant professor Dr Purandhi Rupamani has been granted patent by the government of India. The SRHU authority further claimed in the statement that the stent would make heart treatment affordable for all, adding that the use of medicines in treatment (medicine load) would now be almost eliminated after angioplasty.
While congratulating Dr Rupamani, the chancellor, SRHU Vijay Dhasmana said that the stent is all set to prove to be a boon for humanity and particularly for those suffering from heart-related ailments by making heart treatment quite affordable in the coming days. Speaking of the focus of the university since its inception on research and innovation, he said that new medicinal inventions are in the offing with research work being carried on in the university’s state-of-the-art laboratories.
Notably, the Government of India granted the patent for the ‘Development of Dual Drug Eluting Stent of the Treatment of Coronary Artery Disease’ by Dr Purandhi.
While explaining ‘stent’, Dr Purandhi said that this patent could bring three major benefits to the heart patients in the future. The first benefit is the reduction in the cost of stents. While foreign companies are producing drug-eluting stents whose cost range from Rs one to two lakhs, this new stent has been developed using generic drugs, making the cost of the stent approximately half the price of other stents available in the market, she said. The second benefit is reduction in the consumption of medicines after treatment and the third benefit is the reduced thickness of the stent. She claimed that though human trials for the stent are yet to be conducted it showed a success rate of over 90% in the 28-day testing on mice. She further revealed that the ‘stent’ would undergo pre-clinical trials on larger animals such as pigs and rabbits, adding that the cost of the ‘stent’ made in India would be much lower than the cost of foreign stents.
